Haw Par Corporation Limited (HAWPY) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Haw Par Corporation Limited (HAWPY) opera en el sector Healthcare, cotizado por última vez a $ con una capitalización de mercado de 0. La acción obtiene una puntuación de 50/100, una calificación moderada basada en 9 KPI cuantitativos.
Ultimo analisis: 16 mar 2026Haw Par Corporation Limited (HAWPY) Resumen de Asistencia Médica y Tuberías
Haw Par Corporation Limited, based in Singapore, manufactures and distributes healthcare products, notably Tiger Balm, across Asia and internationally. The company diversifies its revenue streams through investments in securities, property ownership, and leisure alternatives like oceanariums, positioning it uniquely within the drug manufacturing sector with a blend of healthcare and investment activities.
Tesis de Inversión
Haw Par Corporation presents a compelling investment case due to its established brand recognition with Tiger Balm and Kwan Loong, generating consistent revenue in the healthcare sector. The company's diversified business model, including investments and property holdings, provides stability and additional income streams. With a P/E ratio of 12.38 and a high dividend yield of 9.43%, the company offers potential value and income for investors. However, potential risks include fluctuations in investment income and economic conditions affecting property values. The company's beta of 0.21 indicates low volatility compared to the market. Key catalysts include expanding the reach of its healthcare products into new markets and optimizing its investment portfolio.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market capitalization of $2.96 billion, reflecting its significant presence in the healthcare sector.
- P/E ratio of 12.38, suggesting a potentially undervalued stock compared to its earnings.
- High profit margin of 115.4%, indicating efficient operations and strong pricing power.
- Gross margin of 56.0%, demonstrating effective cost management in its manufacturing and distribution processes.
- Dividend yield of 9.43%, offering a substantial income stream for investors.
Competidores y Pares
Fortalezas
- Strong brand recognition with Tiger Balm.
- Diversified business model.
- High profit margin.
- Established distribution network.
Debilidades
- Dependence on a limited number of key products.
- Exposure to fluctuations in investment income.
- Geographic concentration in Asia.
- Limited presence in developed markets outside Asia.
Catalizadores
- Ongoing: Expansion of Tiger Balm product line into new international markets, particularly in emerging economies.
- Ongoing: Strategic investments in quoted securities to generate additional income.
- Upcoming: Potential acquisitions of complementary businesses in the healthcare or leisure sectors.
- Upcoming: Development and launch of new healthcare products targeting specific consumer needs.
- Ongoing: Optimization of the property portfolio to maximize rental income and occupancy rates.
Riesgos
- Potential: Fluctuations in currency exchange rates, particularly between the Singapore Dollar and the U.S. Dollar, affecting ADR returns.
- Ongoing: Intense competition in the healthcare industry from established and emerging players.
- Potential: Economic downturns affecting investment income and property values.
- Ongoing: Regulatory changes in the healthcare sector impacting product approvals and marketing practices.
- Potential: Product liability claims or recalls affecting the reputation and sales of Tiger Balm.
Oportunidades de crecimiento
- Expanding Tiger Balm's market reach into new geographic regions, particularly in emerging markets with growing middle classes and increasing healthcare spending. This expansion could involve strategic partnerships, targeted marketing campaigns, and adapting product formulations to local preferences. The global market for topical pain relief is projected to reach billions of dollars, offering substantial growth potential for Haw Par.
- Developing new product lines and formulations within the healthcare segment to cater to evolving consumer needs and preferences. This could include innovative delivery methods, natural ingredients, and products targeting specific pain conditions. Investing in research and development to create differentiated products can enhance Haw Par's competitive advantage and drive revenue growth.
- Optimizing the investment portfolio to maximize returns and generate consistent income. This involves actively managing the allocation of assets, identifying undervalued securities, and diversifying investments across different sectors and geographies. Effective investment management can contribute significantly to Haw Par's overall profitability and financial stability.
- Enhancing the value of the property portfolio through strategic acquisitions, renovations, and tenant management. This could involve acquiring properties in prime locations, upgrading existing facilities, and attracting high-quality tenants. Maximizing occupancy rates and rental income can generate a stable and recurring revenue stream for Haw Par.
- Leveraging digital channels and e-commerce platforms to expand the distribution and marketing of Tiger Balm and other healthcare products. This includes developing a strong online presence, engaging with consumers through social media, and offering convenient online purchasing options. E-commerce can provide access to a wider customer base and enhance brand awareness.
Oportunidades
- Expanding into new geographic markets.
- Developing new product lines.
- Optimizing the investment portfolio.
- Enhancing the value of the property portfolio.
Amenazas
- Intense competition in the healthcare industry.
- Stringent regulatory requirements.
- Economic downturns affecting investment income and property values.
- Currency fluctuations.
Ventajas competitivas
- Strong brand recognition and reputation for Tiger Balm and Kwan Loong.
- Diversified business model with multiple revenue streams.
- Established distribution network in Asia and internationally.
- Experienced management team with a proven track record.
Acerca de HAWPY
Haw Par Corporation Limited was incorporated in 1969 and is headquartered in Singapore. The company's core business revolves around the manufacturing, marketing, and trading of healthcare products, with a primary focus on topical analgesics. Its flagship products, Tiger Balm and Kwan Loong, are widely recognized brands in Asia and beyond. These products are manufactured and distributed through the company's Healthcare segment. Beyond healthcare, Haw Par diversifies its operations through an Investments segment, which invests in quoted securities. The company also owns and leases investment properties, comprising 45,324 square meters of commercial and industrial space in Singapore and Malaysia. Additionally, Haw Par operates leisure businesses, including oceanariums, providing family and tourist-oriented attractions. The company also leases land, buildings, and office space and offers management support services. This diversified approach allows Haw Par to maintain a presence in multiple sectors, balancing healthcare product sales with investment income and property revenue.
Qué hacen
- Manufactures and distributes topical analgesic products under the Tiger Balm and Kwan Loong brands.
- Invests in quoted securities.
- Owns and leases investment properties in Singapore and Malaysia.
- Provides family and tourist-oriented leisure alternatives, such as oceanariums.
- Leases land, buildings, and office space.
- Offers management support services.
Modelo de Negocio
- Generates revenue from the sale of healthcare products, primarily Tiger Balm and Kwan Loong.
- Earns income from investments in quoted securities.
- Collects rental income from investment properties.
- Derives revenue from leisure attractions, such as oceanariums.
Contexto de la Industria
Haw Par Corporation operates within the global drug manufacturing industry, which is characterized by intense competition, stringent regulatory requirements, and continuous innovation. The market for topical analgesics, where Tiger Balm competes, is driven by consumer demand for pain relief products. The company's investment segment is subject to market volatility and economic cycles. Its property holdings are influenced by real estate market conditions in Singapore and Malaysia. Haw Par's diversified approach allows it to navigate industry-specific challenges and capitalize on opportunities across different sectors.
Clientes Clave
- Consumers seeking topical pain relief products.
- Tenants leasing commercial and industrial space.
- Tourists and families visiting leisure attractions.
- Investors in quoted securities.
Finanzas
Gráfico e información
Precio de la acción de Haw Par Corporation Limited (HAWPY): Price data unavailable
Últimas noticias
-
Is Haw Par Corporation Limited's (SGX:H02) Recent Stock Performance Influenced By Its Financials In Any Way?
Yahoo! Finance: HAWPY News · 12 ene 2026
-
Those who invested in Haw Par (SGX:H02) three years ago are up 98%
Yahoo! Finance: HAWPY News · 22 dic 2025
-
Haw Par (SGX:H02) Ticks All The Boxes When It Comes To Earnings Growth
Yahoo! Finance: HAWPY News · 24 nov 2025
-
Haw Par Corporation Limited's (SGX:H02) top owners are private companies with 36% stake, while 35% is held by individual investors
Yahoo! Finance: HAWPY News · 28 oct 2025
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para HAWPY.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para HAWPY.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de HAWPY en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Últimas Noticias
Is Haw Par Corporation Limited's (SGX:H02) Recent Stock Performance Influenced By Its Financials In Any Way?
Those who invested in Haw Par (SGX:H02) three years ago are up 98%
Haw Par (SGX:H02) Ticks All The Boxes When It Comes To Earnings Growth
Haw Par Corporation Limited's (SGX:H02) top owners are private companies with 36% stake, while 35% is held by individual investors
Liderazgo: Ee Lim Wee
CEO
Ee Lim Wee serves as the Chief Executive Officer of Haw Par Corporation Limited. Information regarding Mr. Wee's detailed career history, education, and previous roles is not available in the provided data. Further research would be needed to provide a comprehensive background.
Historial: Due to limited information available in the provided data, a detailed track record of Mr. Wee's key achievements, strategic decisions, and company milestones under their leadership cannot be accurately assessed. Further research is necessary to evaluate their performance and contributions to Haw Par Corporation Limited.
Información de ADR de Haw Par Corporation Limited No patrocinado
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. HAWPY is traded as a Level 1 ADR, meaning it trades over-the-counter (OTC) without as stringent SEC requirements as listed stocks. This allows U.S. investors to invest in Haw Par Corporation Limited without directly dealing with foreign exchanges.
- Ticker del mercado local: Singapore Exchange (SGX), Singapore
- Nivel de ADR: 1
- Ratio de ADR: 1:1
- Ticker del mercado local: HAWP
Información del mercado OTC de HAWPY
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies in this tier often have limited or no financial disclosure, and may not meet minimum listing requirements of major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and regulatory oversight.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure increases the risk of investing in HAWPY.
- Low liquidity can make it difficult to buy or sell shares.
- Lack of regulatory oversight increases the potential for fraud or mismanagement.
- Price volatility can be higher due to limited trading activity.
- Information asymmetry can disadvantage investors.
- Verify the company's registration and legal status.
- Obtain and review any available financial statements.
- Assess the company's management team and their track record.
- Research the company's industry and competitive landscape.
- Understand the company's business model and revenue streams.
- Evaluate the company's risk factors and potential liabilities.
- Consult with a financial advisor before investing.
- Established brand recognition with Tiger Balm.
- Long operating history since 1969.
- Diversified business model with multiple revenue streams.
- Presence in multiple geographic markets.
Acciones de Haw Par Corporation Limited: Preguntas Clave Respondidas
¿Cuáles son los factores clave para evaluar HAWPY?
Haw Par Corporation Limited (HAWPY) actualmente tiene una puntuación IA de 50/100, indicando puntuación moderada. Fortaleza clave: Strong brand recognition with Tiger Balm.. Riesgo principal a monitorear: Potential: Fluctuations in currency exchange rates, particularly between the Singapore Dollar and the U.S. Dollar, affecting ADR returns.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de HAWPY?
HAWPY actualmente puntúa 50/100 (Grado C) en el MoonshotScore, lo que sugiere calificación moderada. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de HAWPY?
Los precios de HAWPY se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre HAWPY?
La cobertura de analistas para HAWPY incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en HAWPY?
Las categorías de riesgo para HAWPY incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Fluctuations in currency exchange rates, particularly between the Singapore Dollar and the U.S. Dollar, affecting ADR returns.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de HAWPY?
La relación P/E para HAWPY compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está HAWPY sobrevalorada o infravalorada?
Determinar si Haw Par Corporation Limited (HAWPY) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de HAWPY?
Haw Par Corporation Limited (HAWPY) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Limited information available for CEO background and track record.
- Disclosure status on OTC markets is unknown.